New study shows long-term durability of early combination therapy in patients newly diagnosed with type 2 diabetes



A new study, VERIFY (Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes) presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain (16-20 Sept, 2019), and published simultaneously in The Lancet, is the first to show that early combination therapy using vildagliptin and metformin in patients newly diagnosed with type 2 diabetes (T2D) leads to better long-term blood sugar control and a reduced rate of treatment failure than metformin alone (the current standard-of-care treatment for patients newly diagnosed with T2D).



Source link

Leave a Reply!

So glad to see you sticking around!

Want to be the first one to receive the new stuff?

Enter your email address below and we'll send you the goodies straight to your inbox.

Thank You For Subscribing!

This means the world to me!

Spamming is not included! Pinky promise.